Why the study?
Restenosis still occurs in patients receiving DES because mTOR inhibitors slow endothelial repair and cause chronic inflammation, and most mechanistic studies and therapeutic screening efforts do not consider multicellular crosstalk or extracellular matrix components.
Population
Patients receiving DES after PCI
Design
Review
Answers are grounded in this paper and cite their sources.
Review highlights multicellular crosstalk driving restenosis after drug-eluting stent implantation, suggesting organ-on-a-chip systems for therapeutic screening.
Restenosis, the re-narrowing of arteries after percutaneous coronary intervention (PCI), occurs when vascular injury activates smooth muscle cell (SMC) proliferation, leading to neointimal hyperplasia. Drug-eluting stents (DES) inhibit this process by delivering mTOR inhibitors to suppress SMC growth. However, these drugs also slow endothelial repair and cause chronic inflammation. Therefore, restenosis still occurs in patients receiving DES. This review summarizes the signaling pathways in SMCs, endothelial cells (ECs), and monocytes/macrophages that contribute to restenosis. Although cell culture experiments have investigated individual signaling pathways in different cell types, cell behavior is regulated by cell–cell and cell–microenvironment crosstalk. This review highlights the role of growth factors, cytokines, exosomes, and microparticles in multicellular crosstalk after vascular injury. Cell crosstalk and components in the extracellular matrix are not considered in most mechanistic studies and therapeutic screening efforts aimed at improving PCI outcomes. Cell culture models that incorporate multicellular crosstalk and extracellular matrix will provide a better picture of drug response, allowing cell-specific effects and potential side effects to be observed. Future studies using multicellular models and organ-on-a-chip platforms have the potential to enable high-throughput drug screening in physiologically relevant systems to support the development of therapeutics and DES following PCI.
No takes yet. Share an insight, caveat, or question.
Chatha et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: